Results 141 to 150 of about 145,320 (184)

Comparison of the efficacy of obinutuzumab versus rituximab combined with tacrolimus in the treatment of refractory membranous nephropathy. [PDF]

BMC Nephrol
Zhang Y, Guo M, Bian Q, Li S, Sun J, Qin Z, Xu J, Dong R.   +7 more
europepmc   +1 more source

Obinutuzumab Treatment in Rituximab- and Bortezomib-Resistant Phospholipase A2 Receptor Antibody-Positive Membranous Nephropathy. [PDF]

Cureus
Yildirim U, Ozkurt S, Yalcin AU.
europepmc   +1 more source

Comparison of the efficacy of low, moderate and standard doses of rituximab in the treatment of membranous nephropathy. [PDF]

Front Med (Lausanne)
Guo M, Wan W, Li J, Wu S, Ruan Z, Wang R, Zhang Z, Geng X, Hu X, Ren H.   +9 more
europepmc   +1 more source

Is Obinutuzumab the Answer to Primary Membranous Nephropathy Resistant to Rituximab? [PDF]

Kidney Int Rep
Giri K, Glassock RJ, Fervenza FC.
europepmc   +1 more source

Living Donor Kidney Transplantation in High-Recurrence Kidney Diseases: Precision Risk Stratification and Management. [PDF]

Kidney Int Rep
Verhellen C, Devresse A, Gillion V, Van Regemorter E, Darius T, Buemi A, Goffin E, Kanaan N.   +7 more
europepmc   +1 more source

Obinutuzumab in the treatment of idiopathic refractory membranous nephropathy: an observational case series. [PDF]

Front Med (Lausanne)
Zhao X, Chang X, Wang Y, Chen D, Yu M, Zhao J, Zhu H, Mao Y, Juan C.   +8 more
europepmc   +1 more source

First Description of Nonlupus Full-House Nephropathy in Systemic Juvenile Idiopathic Arthritis Responsive to High-Dose Tocilizumab. [PDF]

Kidney Med
Jacobs L, Badot V, Nagant C, Ghorra N, Corazza F, Bienfait L, Nortier J, Taghavi M.   +7 more
europepmc   +1 more source

The value of renal biopsy in PLA₂R- antibody-positive patients with proteinuria: impact of additional pathologies on management and prognosis in a Chinese Cohort. [PDF]

Front Physiol
Lu S, Wang X, Wang X, Zhao M, Li H, Zhao Z.   +5 more
europepmc   +1 more source

Antibody-induced internalization and degradation of PLA2R amplifies CD4⁺ T cell activation. [PDF]

Theranostics
Liu Y, Li Y, Zhou H, Yu J, Deng P, Xu W, Pan B, Zhang L, Zhou H, Zhang J, Liu X, Shi M, Dong X, Tong B, Bi E, Guo N, Hu Y.   +16 more
europepmc   +1 more source

Serum PLA2R-IgG4/PLA2R-IgG ratio dynamics reveal pathogenic autoantibody subclass switch during progression of PLA2R-associated membranous nephropathy. [PDF]

Ann Med
Zhong Y, Liu Y, Zhou D, Tian J, Chen D, Liang D, Liang S, Zhen T, Zhu X, Huang B, Zeng C.   +10 more
europepmc   +1 more source